The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachiglio, Anna Maria, Fenizia, Francesca, Piccirillo, Maria Carmela, Galetta, Domenico, Crinò, Lucio, Vincenzi, Bruno, Barletta, Emiddio, Pinto, Carmine, Ferraù, Francesco, Lambiase, Matilde, Montanino, Agnese, Roma, Cristin, Ludovini, Vienna, Montagna, Elisabetta Sara, De Luca, Antonella, Rocco, Gaetano, Botti, Gerardo, Perrone, Francesco, Morabito, Alessandro, Normanno, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468673/
https://www.ncbi.nlm.nih.gov/pubmed/30857358
http://dx.doi.org/10.3390/cancers11030341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468673/
https://www.ncbi.nlm.nih.gov/pubmed/30857358
http://dx.doi.org/10.3390/cancers11030341

Ejemplares similares